| Outcome Measures: |
Primary: o Maximum observed plasma drug concentration (Cmax), Plasma PK parameter for plazomicin before and after IHD, 30 days|o Time to maximum observed plasma concentration (Tmax), Plasma PK parameter for plazomicin before and after IHD, 30 days|o Area under the plasma concentration time curve from time 0 to the last measurable concentration (AUC0-t), Plasma PK parameter for plazomicin before and after IHD, 30 days|o Area under the plasma concentration time curve extrapolated to infinity (AUCinf), Plasma PK parameter for plazomicin before and after IHD, 30 days|o Terminal elimination half-life (t1/2), Plasma PK parameter for plazomicin before and after IHD, 30 days|o Total plasma clearance (CL), Plasma PK parameter for plazomicin before and after IHD, 30 days|o Volume of distribution during the terminal elimination phase (Vz), Plasma PK parameter for plazomicin before and after IHD, 30 days|o Terminal elimination rate constant (λz), Plasma PK parameter for plazomicin before and after IHD, 30 days | Secondary: • Adverse events (AEs), Safety assessment; An overall summary will be generated presenting the frequency and percentage of subjects and the number of treatment-emergent adverse events (TEAEs)., 30 days | Other: o Cumulative amount of drug excreted in dialysate (Ae), Dialysate PK parameter for plazomicin after IHD, 30 days|o Percent of plazomicin recovered in dialysate (Ae%), Dialysate PK parameter for plazomicin after IHD, 30 days|o Dialysate clearance (CLD), Dialysate PK parameter for plazomicin after IHD, 30 days
|
